Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021

[1]  M. H. Murad,et al.  All‐Cause and Cause‐Specific Mortality in Psoriatic Arthritis and Ankylosing Spondylitis: A Systematic Review and Meta‐Analysis , 2021, Arthritis care & research.

[2]  E. Soriano,et al.  Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis , 2021, Annals of the Rheumatic Diseases.

[3]  P. Gisondi,et al.  Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis , 2021, Annals of the Rheumatic Diseases.

[4]  K. Papp,et al.  AB0559 EFFICACY AND SAFETY OF RISANKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AFTER INADEQUATE RESPONSE OR INTOLERANCE TO DMARDs: 24-WEEK RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND KEEPsAKE 1 TRIAL , 2021 .

[5]  A. Orbai,et al.  POS1020 EFFICACY OF TOFACITINIB ON DACTYLITIS IN INDIVIDUAL DIGITS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS , 2021 .

[6]  D. M. van der Heijde,et al.  Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study , 2021, Annals of the Rheumatic Diseases.

[7]  M. Magrey,et al.  Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. , 2021, The New England journal of medicine.

[8]  L. Coates,et al.  GRAPPA Treatment Recommendations: An Update From the 2020 GRAPPA Annual Meeting , 2021, The Journal of Rheumatology. Supplement.

[9]  W. Tillett,et al.  Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2 , 2020, Annals of the Rheumatic Diseases.

[10]  L. Coates,et al.  Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial , 2020, Annals of the Rheumatic Diseases.

[11]  P. Mease,et al.  Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials , 2020, Annals of the Rheumatic Diseases.

[12]  A. Gottlieb,et al.  OP0230 EFFICACY AND SAFETY OF TILDRAKIZUMAB, A HIGH-AFFINITY ANTI–INTERLEUKIN-23P19 MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS IN A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-DOSE, PHASE 2B STUDY , 2020 .

[13]  M. D. de Wit,et al.  The GRAPPA-OMERACT Working Group: 4 Prioritized Domains for Completing the Core Outcome Measurement Set for Psoriatic Arthritis 2019 Updates , 2020, The Journal of Rheumatology. Supplement.

[14]  L. Coates,et al.  GRAPPA Treatment Recommendations: Updates and Methods , 2020, The Journal of Rheumatology. Supplement.

[15]  A. Gottlieb,et al.  Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial , 2020, The Lancet.

[16]  R. Ribeiro,et al.  GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis , 2020, Annals of the rheumatic diseases.

[17]  A. Gottlieb,et al.  Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial , 2020, The Lancet.

[18]  G. Guyatt,et al.  2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases , 2020, Arthritis & rheumatology.

[19]  D. Heijde,et al.  Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial , 2019, The Lancet.

[20]  P. Emery,et al.  A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial , 2019, Annals of the rheumatic diseases.

[21]  L. Coates,et al.  Psoriatic arthritis , 2019, Nature Reviews Disease Primers.

[22]  A. Kavanaugh,et al.  Bedside to bench: defining the immunopathogenesis of psoriatic arthritis , 2019, Nature Reviews Rheumatology.

[23]  D. Gladman,et al.  Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial , 2019, Arthritis & rheumatology.

[24]  M. Nurmohamed,et al.  Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate , 2019, Annals of the rheumatic diseases.

[25]  A. Ogdie,et al.  Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition , 2019, Nature Reviews Rheumatology.

[26]  G. Schett,et al.  Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study. , 2019, Seminars in arthritis and rheumatism.

[27]  D. Gladman,et al.  Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis , 2019, Arthritis Research & Therapy.

[28]  D. Heijde,et al.  Three Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis , 2018, Arthritis & rheumatology.

[29]  R. Landewé,et al.  Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial , 2018, The Lancet.

[30]  M. Vatn,et al.  Peripheral arthritis in patients with long-term inflammatory bowel disease. Results from 20 years of follow-up in the IBSEN study , 2018, Scandinavian journal of gastroenterology.

[31]  D. M. van der Heijde,et al.  Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study , 2018, Annals of the rheumatic diseases.

[32]  A. Gottlieb,et al.  Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis , 2017, Annals of the rheumatic diseases.

[33]  M. D. de Wit,et al.  Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group , 2017, The Journal of Rheumatology.

[34]  M. D. de Wit,et al.  A Multicenter Nominal Group Study to Rank Outcomes Important to Patients, and Their Representation in Existing Composite Outcome Measures for Psoriatic Arthritis , 2017, The Journal of Rheumatology.

[35]  Fernando Pimentel-Santos,et al.  Gender differences among patients with primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease in an iberoamerican spondyloarthritis cohort , 2016, Medicine.

[36]  P. Mease,et al.  Efficacy of Subcutaneous Secukinumab in Patients with Active Psoriatic Arthritis Stratified by Prior Tumor Necrosis Factor Inhibitor Use: Results from the Randomized Placebo-controlled FUTURE 2 Study , 2016, The Journal of Rheumatology.

[37]  R. Scrivo,et al.  Psoriasis and Psoriatic Arthritis-Related Uveitis: Different Ophthalmological Manifestations and Ocular Inflammation Features , 2016, Seminars in ophthalmology.

[38]  D. M. van der Heijde,et al.  Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study , 2016, Annals of the rheumatic diseases.

[39]  A. Gottlieb,et al.  Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis , 2016, Arthritis & rheumatology.

[40]  L. Coates,et al.  Methotrexate Efficacy in the Tight Control in Psoriatic Arthritis Study , 2016, The Journal of Rheumatology.

[41]  A. Gottlieb,et al.  Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Treatment Recommendations for Psoriatic Arthritis 2015 , 2015 .

[42]  D. M. van der Heijde,et al.  Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. , 2015, The New England journal of medicine.

[43]  M. Akker,et al.  Clinical features and types of articular involvement in patients with psoriatic arthritis , 2015, Clinical Rheumatology.

[44]  L. Coates,et al.  Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial , 2014, The Lancet.

[45]  D. Gladman,et al.  The Path Forward to Biomarker Discovery in Psoriatic Disease: A Report from the GRAPPA 2010 Annual Meeting , 2012, The Journal of Rheumatology.

[46]  W. Boehncke.  Epidemiology and Potential Pathomechanisms of Cardiovascular Comorbidities in Psoriasis: A Report from the GRAPPA 2010 Annual Meeting , 2012, The Journal of Rheumatology.

[47]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[48]  A. Gottlieb,et al.  Treatment recommendations for psoriatic arthritis , 2008, Annals of the rheumatic diseases.

[49]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[50]  M. Tsechkovski,et al.  WHO Regional Office for Europe , 1993, The Lancet.